| 沙利度胺联合VAD治疗多发性骨髓瘤的疗效观察 |
| |
| 引用本文： | 王木新. 沙利度胺联合VAD治疗多发性骨髓瘤的疗效观察[J]. 世界临床药物, 2007, 28(4): 238-240 |
| |
| 作者姓名： | 王木新 |
| |
| 作者单位： | 淄博市中心医院,血液科 |
| |
| 摘 要： | 目的 观察沙利度胺(反应停)联合VAD方案(长春新碱 多柔比星 地塞米松)治疗多发性骨髓瘤(MM)的疗效及不良反应.方法 29例MM患者接受沙利度胺联合VAD治疗方案:沙利度胺自VAD方案开始持续给药,一日200 mg,以后每周递增100 mg,直至一日400～600 mg;每间隔4周接受VAD化疗1次.结果 部分缓解18例,进步7例,无效4例,总有效率为86.2%.常见不良反应为皮疹、便秘、嗜睡、乏力、头昏和水肿等.结论 沙利度胺联合VAD方案治疗MM反应率高,不良反应少,耐受性好.
|
| 关 键 词： | 多发性骨髓瘤 沙利度胺 化疗 |
| 文章编号： | 1672-9188（2007）04-238-03 |
| 修稿时间： | 2006-12-18 |
Clinical Efficacy of Thalidomide with Vinblastine and Doxorubicin and Dexamethasone in the Multiple Myeloma |
| |
| Wang Mu-xin. Clinical Efficacy of Thalidomide with Vinblastine and Doxorubicin and Dexamethasone in the Multiple Myeloma[J]. WORLD CLINICAL DRUGS, 2007, 28(4): 238-240 |
| |
| Authors: | Wang Mu-xin |
| |
| Affiliation: | Department of Hematology, Zi Bo Central HospitaI,Shandong |
| |
| Abstract: | Objective To evaluate the effecacy and safety of thalidomide with vinblastine and doxorubicin and dexamethasone (VAD) in the treatment of multiple myeloma(MM). Methods 29 patients with MM received the treatment of thalidomide with VAD.The initial dose of thalidomide was 200mg/d, then does increased 100mg/d to 400-600mg/d every week until the maximal tolerance.Chemotherapy with VAD daily for every four weeks was accompanied in all patients. Result Among the 29 patients, 18 achieved partial remission (PR), 7 improved and 4 had no effect. Total effective rate was 86.2%. Conclusion Thalidomide can be used in the treatment of MM and it can be tolerable. |
| |
| Keywords: | multiple myeloma thalidomide chemotherapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
